
Experimental pill that promises new hope for deadly pancreatic cancer accelerated
A randomized clinical trial showed that patients receiving daraxonrasib achieved a median survival of 13.2 months

A randomized clinical trial showed that patients receiving daraxonrasib achieved a median survival of 13.2 months

The international scientific community demonstrated an extraordinary capacity for innovation this year

Unlike other types of cancer where medical advances have improved survival rates, pancreatic cancer has remained a challenge